Another Phase II with an Anit-Tau antibody (AbbVie)

Does this bode well for the ‘front runner’ Axon especially after TauRx fell at the first?

And what about the others in the pack at the back: Eisai/Biogen, Bristol-Myers Squibb and Astellas? >>>>

eyJpIjoiWWprNU56UmhPR1ppT1RFeCIsInQiOiJxTTlsOWcxaWZkU3YwVmF2TFFYOUhNTVg1eDJpTVVPWGRVUGN4cXdFSjlLMzcyM2J6Tld0OWc2OEpjekE2MGdBeVJORmFWelZ5Sk5yNkdadSs1VkhKajMwYjRBSGthdHlFbHVFRGh6UWo5aHdyNjJLclY1NnpPb0RlQ25GWjdVRCJ9